Novel Pharmaceutical Excipients Needed To Keep Up With Development Of Novel Drugs For Cancer And Inflammatory Diseases

COVID-19 Also Fueled Growth Of Excipients Market

May 01, 2021

Excipients are an essential part of the drug formulation process and affect drug delivery. Specific drug delivery systems and technologies have tremendous influence on the adoption of novel drugs.

The increase in development of novel drugs for treatment of cancer, rheumatoid arthritis and other inflammatory diseases are driving the excipients market, according to the BCC report, Excipients in Pharmaceuticals: Global Markets to 2026.

Additionally, the Covid-19 pandemic fueled further R&D activities for vaccines and coronavirus treatments, positively impacting the excipients market.

There is a strong need for the development of novel excipients. Excipients for solid dosage forms like controlled release drugs, multifunctional excipients and technological advancements in nanotechnology and liposome development are also boosting growth in the market.

Report Highlights

  • The global market for pharmaceutical excipients should grow from USD 8.3 billion in 2021 to USD 10.6 billion by 2026, at a compound annual growth rate (CAGR) of 5%.
  • Organic pharmaceutical excipients should grow from USD 7.8 billion in 2021 to USD 9.8 billion by 2026 at a CAGR of 5%.
  • Key market players: Cargill, BASF and Croda and  Roquette Feres.

Explore the full report here:

Excipients in Pharmaceuticals: Global Markets to 2026( PHM010L )
Publish Date: Apr 2021    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.